<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875287</url>
  </required_header>
  <id_info>
    <org_study_id>J18115</org_study_id>
    <secondary_id>IRB00182038</secondary_id>
    <secondary_id>ASTX727</secondary_id>
    <nct_id>NCT03875287</nct_id>
  </id_info>
  <brief_title>Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study of the combination of cedazuridine with decitabine in patients with
      solid tumors. At least 6 patients will be enrolled per treatment level to assess optimal
      hypomethylation and toxicity (up to 30 patients total).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of combination cedazuridine with decitabine as assessed by number of participants who experience adverse events</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of participants who have experienced grade 3 or higher adverse events, as defined by Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) as determined by number of participants with of dose limiting toxicities (DLT)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Maximum tolerated dose will be determined by the maximum dose at which the least number of participants experience dose-limiting toxicity. The dose limiting toxicity is defined using the Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASTX727 in solid tumor patients as measured by total exposure</measure>
    <time_frame>Day 2</time_frame>
    <description>Total exposure will be calculated as area under the plasma concentration-time curve (AUC) by using non-compartmental methods (Winonlin, version 5.3 or newer) and/or compartmental modeling (Adapt II, release 4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASTX727 in solid tumor patients as measured by maximum concentration (Cmax)</measure>
    <time_frame>Day 2</time_frame>
    <description>Cmax (mmol/L) is defined as the maximum concentration of ASTX727 in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASTX727 in solid tumor patients as measured by time to maximum concentration (Tmax)</measure>
    <time_frame>Day 2</time_frame>
    <description>Tmax (minutes) is defined as the time to reach maximum concentration of ASTX727 in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) in solid tumor patients who are treated with ASTX727</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Proportion of participants who had measurable disease at baseline and have been re-evaluated after at least 1 cycle of therapy with observed reduction in tumor burden as defined by RECIST 1.1: Complete response (CR)= disappearance of all target lesions, Partial response (PR)= at least 30% decrease in sum of diameters of target lesions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Decitabine and Cedazuridine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will be administered on an outpatient basis. Cycle length is 28 days. The dose of cedazuridine is fixed at 100mg and the dose and duration of decitabine will vary depending on when a patient enters the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>DOSING REGIMEN(S):
Level -1 5mg daily days 1-10
Level 1 5mg daily days 1-14
Level 2 10mg daily days 1-14
Level 3 15mg daily days 1-14</description>
    <arm_group_label>Decitabine and Cedazuridine</arm_group_label>
    <other_name>Dacogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cedazuridine</intervention_name>
    <description>DOSING REGIMEN(S):
Level -1 100mg daily days 1-10
Level 1 100mg daily days 1-14
Level 2 100mg daily days 1-14
Level 3 100mg daily days 1-14</description>
    <arm_group_label>Decitabine and Cedazuridine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have advanced, unresectable, and/or metastatic solid tumor
             malignancy that is histologically or cytologically confirmed.

          -  Patients must have received at least 2 lines of therapy in the advanced/metastatic
             setting (if 2 lines exist) and have no other possible therapies or refuse therapies
             that have shown clinical benefit for their condition.

          -  ECOG performance status &lt;1

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Patients must have measurable disease

          -  Ability to swallow oral medications

        Exclusion Criteria:

          -  Participants who have had chemotherapy or radiotherapy within 3 weeks

          -  Participants may not be receiving any other investigational agents.

          -  Active hepatitis B or hepatitis C infection.

          -  Active or untreated gastric or duodenal ulcer

          -  Symptomatic bowel obstruction within 3 months prior to screening visit.

          -  Symptomatic ascites in the last 4 weeks

        Other protocol defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nilofer Azad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Hale</last_name>
    <phone>410-502-5140</phone>
    <email>phase1trials@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorraine Martinez</last_name>
      <email>Lorraine.Martinez@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenn Hale</last_name>
      <email>phase1trials@exchange.johnshopkins.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

